ArticleIndian journal of clinical biochemistry : IJCB2024
Irisin and Triglyceride Glucose Index as Markers of Dyslipidemia in Young Adults.
Article in Indian journal of clinical biochemistry : IJCB, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Association of Circulating Irisin with Insulin Resistance and Metabolic Risk Markers in Prediabetic and Newly Diagnosed Type 2 Diabetes Patients.International journal of molecular sciences · 2026Article
- Correlation of the triglyceride-glucose index with major adverse cardiovascular events in type 2 diabetes mellitus patients with acute myocardial infarction combined with HFpEF.Frontiers in endocrinology · 2025Article
- Article
- Article
- Cardiometabolic Risk Assessment in a Cohort of Children and Adolescents Diagnosed with Hyperinsulinemia.Diseases (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irisin, is a new myokine, considered a favorable metabolic factor and inversely associated with non-communicable diseases. The biological activities of irisin are currently unknown; however, they include browning white adipose tissue, insulin sensitivity, and anti-inflammatory and antioxidant effects. Triglyceride glucose index is a notable insulin resistance marker that predicts the risk of metabolic dyslipidemia and cardiovascular risk. The study aimed to evaluate the relation of irisin and Triglyceride glucose index (TyG) in young adults to assess the cardiovascular risk. This observational cross-sectional study included 80 participants aged 18 to 35 years (male and females) with cut-off TyG > 4.5 as the prime criteria. With consent, anthropometric measurements were documented. Fasting lipid profile parameters were analyzed, and atherogenic lipid ratios and TyG index were calculated. Serum irisin was analyzed in Bio-Rad ELISA using a standardized Abbkine kit. Decreased irisin levels (0.32 ± 0.04ng/ml) and increased TyG index (4.95 ± 0.012) were observed in the participants with elevated triglyceride levels. The lipid profile parameters and atherogenic lipid ratios were observed to be elevated in males as compared to females. Correlation of irisin with lipid parameters revealed statistically significant positive correlation with HDLc (r = + 0.305) and negative correlation with non-HDLc (r = - 0.393), TC/HDLc (r = -0.508), LDLc/HDLc (r= -0.475) and TyG (r = -0.28). The study concludes that decreased irisin and increased TyG index in young adults reflect the state of metabolic dyslipidemia which enables the identification of individuals with metabolic and atherogenic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.